Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness

Marcia Valenstein, Janet Kavanagh, Todd Lee, Peter Reilly, Gregory W. Dalack, John Grabowski, David Smelson, David L. Ronis, Dara Ganoczy, Emily Woltmann, Tabitha Metreger, Patricia Wolschon, Agnes Jensen, Barbara Poddig, Frederic C. Blow

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Similar to patients with other chronic disorders, patients with serious mental illness (SMI) are often poorly adherent with prescribed medications. Objective: We conducted a randomized controlled trial examining the effectiveness of a pharmacy-based intervention (Meds-Help) in increasing antipsychotic medication adherence among Department of Veterans Affairs (VA) patients with SMI. We also examined the impact of Meds-Help on psychiatric symptoms, quality of life, and satisfaction with care. Methods: We enrolled 118 patients from 4 VA facilities with schizophrenia, schizoaffective, or bipolar disorder who were on long-term antipsychotics but had antipsychotic medication possession ratios (MPRs) <0.8 in the prior year. Patients were randomized to usual care (UC; n = 60) or the pharmacy-based intervention (Meds-Help; n = 58). We reassessed adherence at 6 and 12 months, at which time patients completed Positive and Negative Symptom Scales (PANSS), Quality of Well-being Scales (QWB), and Client Satisfaction Questionnaires (CSQ-8). Results: Prior to enrollment, Meds-Help and UC patients had mean antipsychotic MPRs of 0.54 and 0.55, respectively. At 6 months, mean MPRs were 0.91 for Meds-Help and 0.64 for UC patients; at 12 months, they were 0.86 for Meds-Help and 0.62 for UC patients. In multivariate analyses adjusting for patient factors, Meds-Help patients had significantly higher MPRs at 6 and 12 months (P <. 0001). There were no significant differences between groups in PANSS, QWB, or CSQ-8 scores, but power to detect small effects was limited. Conclusions: Congruent with prior studies of patients with other disorders, a practical pharmacy-based intervention increased antipsychotic adherence among patients with SMI. However, SMI patients may require additional care management components to improve outcomes.

Original languageEnglish (US)
Pages (from-to)727-736
Number of pages10
JournalSchizophrenia bulletin
Volume37
Issue number4
DOIs
StatePublished - Jul 1 2011

Fingerprint

Patient Compliance
Antipsychotic Agents
Veterans
Medication Adherence
Mentally Ill Persons
Bipolar Disorder
Psychotic Disorders
Psychiatry
Schizophrenia
Multivariate Analysis
Randomized Controlled Trials
Quality of Life

Keywords

  • adherence
  • antipsychotic medications
  • health services

Cite this

Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. / Valenstein, Marcia; Kavanagh, Janet; Lee, Todd; Reilly, Peter; Dalack, Gregory W.; Grabowski, John; Smelson, David; Ronis, David L.; Ganoczy, Dara; Woltmann, Emily; Metreger, Tabitha; Wolschon, Patricia; Jensen, Agnes; Poddig, Barbara; Blow, Frederic C.

In: Schizophrenia bulletin, Vol. 37, No. 4, 01.07.2011, p. 727-736.

Research output: Contribution to journalArticle

Valenstein, M, Kavanagh, J, Lee, T, Reilly, P, Dalack, GW, Grabowski, J, Smelson, D, Ronis, DL, Ganoczy, D, Woltmann, E, Metreger, T, Wolschon, P, Jensen, A, Poddig, B & Blow, FC 2011, 'Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness', Schizophrenia bulletin, vol. 37, no. 4, pp. 727-736. https://doi.org/10.1093/schbul/sbp121
Valenstein, Marcia ; Kavanagh, Janet ; Lee, Todd ; Reilly, Peter ; Dalack, Gregory W. ; Grabowski, John ; Smelson, David ; Ronis, David L. ; Ganoczy, Dara ; Woltmann, Emily ; Metreger, Tabitha ; Wolschon, Patricia ; Jensen, Agnes ; Poddig, Barbara ; Blow, Frederic C. / Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. In: Schizophrenia bulletin. 2011 ; Vol. 37, No. 4. pp. 727-736.
@article{f0067bc2a3a943e785f0882c42df662e,
title = "Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness",
abstract = "Background: Similar to patients with other chronic disorders, patients with serious mental illness (SMI) are often poorly adherent with prescribed medications. Objective: We conducted a randomized controlled trial examining the effectiveness of a pharmacy-based intervention (Meds-Help) in increasing antipsychotic medication adherence among Department of Veterans Affairs (VA) patients with SMI. We also examined the impact of Meds-Help on psychiatric symptoms, quality of life, and satisfaction with care. Methods: We enrolled 118 patients from 4 VA facilities with schizophrenia, schizoaffective, or bipolar disorder who were on long-term antipsychotics but had antipsychotic medication possession ratios (MPRs) <0.8 in the prior year. Patients were randomized to usual care (UC; n = 60) or the pharmacy-based intervention (Meds-Help; n = 58). We reassessed adherence at 6 and 12 months, at which time patients completed Positive and Negative Symptom Scales (PANSS), Quality of Well-being Scales (QWB), and Client Satisfaction Questionnaires (CSQ-8). Results: Prior to enrollment, Meds-Help and UC patients had mean antipsychotic MPRs of 0.54 and 0.55, respectively. At 6 months, mean MPRs were 0.91 for Meds-Help and 0.64 for UC patients; at 12 months, they were 0.86 for Meds-Help and 0.62 for UC patients. In multivariate analyses adjusting for patient factors, Meds-Help patients had significantly higher MPRs at 6 and 12 months (P <. 0001). There were no significant differences between groups in PANSS, QWB, or CSQ-8 scores, but power to detect small effects was limited. Conclusions: Congruent with prior studies of patients with other disorders, a practical pharmacy-based intervention increased antipsychotic adherence among patients with SMI. However, SMI patients may require additional care management components to improve outcomes.",
keywords = "adherence, antipsychotic medications, health services",
author = "Marcia Valenstein and Janet Kavanagh and Todd Lee and Peter Reilly and Dalack, {Gregory W.} and John Grabowski and David Smelson and Ronis, {David L.} and Dara Ganoczy and Emily Woltmann and Tabitha Metreger and Patricia Wolschon and Agnes Jensen and Barbara Poddig and Blow, {Frederic C.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1093/schbul/sbp121",
language = "English (US)",
volume = "37",
pages = "727--736",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness

AU - Valenstein, Marcia

AU - Kavanagh, Janet

AU - Lee, Todd

AU - Reilly, Peter

AU - Dalack, Gregory W.

AU - Grabowski, John

AU - Smelson, David

AU - Ronis, David L.

AU - Ganoczy, Dara

AU - Woltmann, Emily

AU - Metreger, Tabitha

AU - Wolschon, Patricia

AU - Jensen, Agnes

AU - Poddig, Barbara

AU - Blow, Frederic C.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background: Similar to patients with other chronic disorders, patients with serious mental illness (SMI) are often poorly adherent with prescribed medications. Objective: We conducted a randomized controlled trial examining the effectiveness of a pharmacy-based intervention (Meds-Help) in increasing antipsychotic medication adherence among Department of Veterans Affairs (VA) patients with SMI. We also examined the impact of Meds-Help on psychiatric symptoms, quality of life, and satisfaction with care. Methods: We enrolled 118 patients from 4 VA facilities with schizophrenia, schizoaffective, or bipolar disorder who were on long-term antipsychotics but had antipsychotic medication possession ratios (MPRs) <0.8 in the prior year. Patients were randomized to usual care (UC; n = 60) or the pharmacy-based intervention (Meds-Help; n = 58). We reassessed adherence at 6 and 12 months, at which time patients completed Positive and Negative Symptom Scales (PANSS), Quality of Well-being Scales (QWB), and Client Satisfaction Questionnaires (CSQ-8). Results: Prior to enrollment, Meds-Help and UC patients had mean antipsychotic MPRs of 0.54 and 0.55, respectively. At 6 months, mean MPRs were 0.91 for Meds-Help and 0.64 for UC patients; at 12 months, they were 0.86 for Meds-Help and 0.62 for UC patients. In multivariate analyses adjusting for patient factors, Meds-Help patients had significantly higher MPRs at 6 and 12 months (P <. 0001). There were no significant differences between groups in PANSS, QWB, or CSQ-8 scores, but power to detect small effects was limited. Conclusions: Congruent with prior studies of patients with other disorders, a practical pharmacy-based intervention increased antipsychotic adherence among patients with SMI. However, SMI patients may require additional care management components to improve outcomes.

AB - Background: Similar to patients with other chronic disorders, patients with serious mental illness (SMI) are often poorly adherent with prescribed medications. Objective: We conducted a randomized controlled trial examining the effectiveness of a pharmacy-based intervention (Meds-Help) in increasing antipsychotic medication adherence among Department of Veterans Affairs (VA) patients with SMI. We also examined the impact of Meds-Help on psychiatric symptoms, quality of life, and satisfaction with care. Methods: We enrolled 118 patients from 4 VA facilities with schizophrenia, schizoaffective, or bipolar disorder who were on long-term antipsychotics but had antipsychotic medication possession ratios (MPRs) <0.8 in the prior year. Patients were randomized to usual care (UC; n = 60) or the pharmacy-based intervention (Meds-Help; n = 58). We reassessed adherence at 6 and 12 months, at which time patients completed Positive and Negative Symptom Scales (PANSS), Quality of Well-being Scales (QWB), and Client Satisfaction Questionnaires (CSQ-8). Results: Prior to enrollment, Meds-Help and UC patients had mean antipsychotic MPRs of 0.54 and 0.55, respectively. At 6 months, mean MPRs were 0.91 for Meds-Help and 0.64 for UC patients; at 12 months, they were 0.86 for Meds-Help and 0.62 for UC patients. In multivariate analyses adjusting for patient factors, Meds-Help patients had significantly higher MPRs at 6 and 12 months (P <. 0001). There were no significant differences between groups in PANSS, QWB, or CSQ-8 scores, but power to detect small effects was limited. Conclusions: Congruent with prior studies of patients with other disorders, a practical pharmacy-based intervention increased antipsychotic adherence among patients with SMI. However, SMI patients may require additional care management components to improve outcomes.

KW - adherence

KW - antipsychotic medications

KW - health services

UR - http://www.scopus.com/inward/record.url?scp=79959737852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959737852&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbp121

DO - 10.1093/schbul/sbp121

M3 - Article

C2 - 19933540

AN - SCOPUS:79959737852

VL - 37

SP - 727

EP - 736

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 4

ER -